L&S Knock-Out 5CV 09.12.2024/ DE000LX34138 /
2024-06-11 5:15:22 PM | Chg.-0.20 | Bid5:15:22 PM | Ask5:15:22 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
2.59EUR | -7.17% | 2.59 Bid Size: - |
2.63 Ask Size: - |
CUREVAC N.V. O.N. | 1.50 EUR | 2024-12-09 | Call |
GlobeNewswire
2022-03-25
US Food and Drug Administration Revises Emergency Use Authorization for Sotrovimab Due to Omicron BA...
GlobeNewswire
2022-01-13
GSK and Vir Submit Emergency Use Authorization Application to FDA for Intramuscular Administration o...
GlobeNewswire
2022-01-11
GSK and Vir Biotechnology Announce United States Government Agreement to Purchase Additional Supply ...
GlobeNewswire
2021-12-17
Xevudy (Sotrovimab) Granted Marketing Authorization by the European Commission for the Early Treatme...
GlobeNewswire
2021-12-07
Preclinical Studies Demonstrate Sotrovimab Retains Activity Against the Full Combination of Mutation...
GlobeNewswire
2021-12-02
Preclinical Data Demonstrate Sotrovimab Retains Activity Against Key Omicron Mutations, New SARS-CoV...
GlobeNewswire
2021-11-17
GSK and Vir Biotechnology Announce United States Government Agreements to Purchase Sotrovimab, a COV...
GlobeNewswire
2021-11-12
Primary endpoint met in COMET-TAIL Phase 3 trial evaluating intramuscular administration of sotrovim...
GlobeNewswire
2021-07-28
GSK and Vir Biotechnology Announce Joint Procurement Agreement with European Commission for COVID-19...
GlobeNewswire
2021-06-21
GSK and Vir Biotechnology Announce Continuing Progress of the COMET Clinical Development Program for...
GlobeNewswire
2021-05-27
GSK and Vir Biotechnology Announce Sotrovimab (VIR-7831) Receives Emergency Use Authorization from t...